364 related articles for article (PubMed ID: 31777761)
1. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
Diamond MP; Stewart EA; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod Open; 2019; 2019(4):hoz027. PubMed ID: 31777761
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
3. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J; Becker C; Taylor H; Carmona Herrera F; Donnez O; Horne A; Paszkowski M; Petraglia F; Renner SP; Patel A; Boolell M; Bestel E; Dolmans MM
Hum Reprod; 2024 Apr; ():. PubMed ID: 38648863
[TBL] [Abstract][Full Text] [Related]
4. Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB).
Yin K; Whitaker L; Hojo E; McLenachan S; Walker J; McKillop G; Stubbs C; Priest L; Cruz M; Roberts N; Critchley H
Hum Reprod Open; 2023; 2023(3):hoad021. PubMed ID: 37304815
[TBL] [Abstract][Full Text] [Related]
5. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
6. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
[TBL] [Abstract][Full Text] [Related]
7. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
[TBL] [Abstract][Full Text] [Related]
9. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.
Whitaker LH; Murray AA; Matthews R; Shaw G; Williams AR; Saunders PT; Critchley HO
Hum Reprod; 2017 Mar; 32(3):531-543. PubMed ID: 28130434
[TBL] [Abstract][Full Text] [Related]
10. ESHRE guideline: endometriosis.
Becker CM; Bokor A; Heikinheimo O; Horne A; Jansen F; Kiesel L; King K; Kvaskoff M; Nap A; Petersen K; Saridogan E; Tomassetti C; van Hanegem N; Vulliemoz N; Vermeulen N;
Hum Reprod Open; 2022; 2022(2):hoac009. PubMed ID: 35350465
[TBL] [Abstract][Full Text] [Related]
11. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
12. Markers of human endometrial hypoxia can be detected in vivo and ex vivo during physiological menstruation.
Reavey JJ; Walker C; Nicol M; Murray AA; Critchley HOD; Kershaw LE; Maybin JA
Hum Reprod; 2021 Mar; 36(4):941-950. PubMed ID: 33496337
[TBL] [Abstract][Full Text] [Related]
13. Preoperative medical therapy before surgery for uterine fibroids.
Lethaby A; Puscasiu L; Vollenhoven B
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD000547. PubMed ID: 29139105
[TBL] [Abstract][Full Text] [Related]
14. World Endometriosis Society consensus on the classification of endometriosis.
Johnson NP; Hummelshoj L; Adamson GD; Keckstein J; Taylor HS; Abrao MS; Bush D; Kiesel L; Tamimi R; Sharpe-Timms KL; Rombauts L; Giudice LC;
Hum Reprod; 2017 Feb; 32(2):315-324. PubMed ID: 27920089
[TBL] [Abstract][Full Text] [Related]
15. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
[TBL] [Abstract][Full Text] [Related]
16. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
17. No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis.
Katalinic A; Noftz MR; Garcia-Velasco JA; Shulman LP; van den Anker JN; Strauss Iii JF
Hum Reprod Open; 2024; 2024(1):hoae004. PubMed ID: 38344249
[TBL] [Abstract][Full Text] [Related]
18. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
19. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
[TBL] [Abstract][Full Text] [Related]
20. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
